摘要
目的探讨孟鲁司特治疗哮喘的疗效,并评价其用药安全性。方法 96例哮喘患者随机平均分为观察组和对照组,每组48例。对照组患者给予哮喘常规治疗,观察组患者在常规治疗的基础上给予孟鲁司特10 mg口服,每晚1次,连用6周。观察两组治疗前后肺功能变化,包括用力肺活量(FVC)、第1 s用力呼气容量(FEV1)及最大呼气峰流速(PEF),并评价两组临床疗效及不良反应。结果观察组治疗后FVC、FEV1、PEF均较治疗前显著升高(P<0.01或P<0.05);对照组仅PEF较治疗前升高(P<0.05);组间比较显示观察组治疗后FVC、FEV1、PEF均高于对照组(P<0.05)。观察组治疗哮喘的有效率显著高于对照组(P<0.01)。两组均未发生明显不良反应。结论孟鲁司特能够显著改善哮喘患者的肺功能,临床用药安全、有效,值得临床推广使用。
Objective To explore the efficacy of montelukast in the treatment of asthma, and to assess its safety. Methods A total of 96 patients with asthma were randomly divided into observation group and control group （each n = 48）. Control group was received routine treatment, and observation group was administered orally with 10 mg once a day for 6 weeks on the basis of routine treatment. The changes of lung functions of the two groups before and after the treatment, including forced vital capacity （FVC）, forced expiratory volume in one second （FEVI） and peak expiratory flow （PEF） were observed. The clinical efficacy and adverse drug reaction （ADR） were also evaluated. Results After the treatment, FVC, FEV1 and PEF of observation group were significantly improved （P 〈 0.01 or P 〈 0.05 ）, only PEF was improved in control group （P 〈 0.05）. After the treatment, FVC, FEV1 and PEF of observation group were statistically higher than those of control group （P 〈 0.05 ）. The effective rate of observation group was significantly higher than that of control group （ P 〈 0.01 ）. No obvious adverse reaction was found in the two groups. Conelusions Montelukast can significantly improve the lung functions of patients with asthma. It is effective and safe, thus worthy of being applied extensively in clinical practice.
出处
《实用预防医学》
CAS
2012年第2期245-246,共2页
Practical Preventive Medicine
关键词
哮喘
孟鲁司特
疗效
安全性
Asthma
Montelukast
Therapeutic effect
Safety
